Virtu Financial LLC Purchases New Holdings in TRxADE HEALTH, Inc. (NASDAQ:MEDS)

Virtu Financial LLC purchased a new stake in TRxADE HEALTH, Inc. (NASDAQ:MEDS) in the second quarter, HoldingsChannel reports. The firm purchased 21,217 shares of the company’s stock, valued at approximately $94,000.

Several other institutional investors also recently modified their holdings of the stock. Blueshift Asset Management LLC acquired a new stake in shares of TRxADE HEALTH in the second quarter valued at approximately $59,000. Renaissance Technologies LLC grew its holdings in TRxADE HEALTH by 176.1% during the 1st quarter. Renaissance Technologies LLC now owns 110,700 shares of the company’s stock worth $580,000 after acquiring an additional 70,600 shares during the period. Finally, Vanguard Group Inc. acquired a new stake in TRxADE HEALTH during the 2nd quarter worth $613,000. 6.24% of the stock is owned by institutional investors and hedge funds.

MEDS opened at $3.47 on Thursday. The firm’s fifty day simple moving average is $4.46 and its 200 day simple moving average is $4.62. TRxADE HEALTH, Inc. has a 12 month low of $3.10 and a 12 month high of $10.82.

TRxADE HEALTH (NASDAQ:MEDS) last issued its quarterly earnings results on Sunday, October 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). TRxADE HEALTH had a negative return on equity of 63.53% and a negative net margin of 72.07%. The business had revenue of $2.55 million for the quarter, compared to the consensus estimate of $1.94 million. During the same period last year, the firm earned $0.02 earnings per share. As a group, equities analysts forecast that TRxADE HEALTH, Inc. will post -0.52 EPS for the current year.

A number of research firms have commented on MEDS. Zacks Investment Research raised shares of TRxADE HEALTH from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Thursday. Maxim Group reissued a “buy” rating and issued a $11.00 price target on shares of TRxADE HEALTH in a report on Wednesday, July 28th. Four research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $9.44.

TRxADE HEALTH Profile

TRxADE HEALTH, Inc provides an online platform for pharmaceutical purchasers. It owns and operates a business-to-business web-based marketplace focuses on the United States pharmaceutical industry. The firm operates web-based market platform that enables trade among healthcare buyers and sellers of pharmaceuticals, accessories and services.

See Also: How are institutional investors different from individual investors?

Want to see what other hedge funds are holding MEDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TRxADE HEALTH, Inc. (NASDAQ:MEDS).

Institutional Ownership by Quarter for TRxADE HEALTH (NASDAQ:MEDS)

Receive News & Ratings for TRxADE HEALTH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRxADE HEALTH and related companies with MarketBeat.com's FREE daily email newsletter.